Kymera Therapeutics Launches Phase 2b Trial of Oral STAT6 Degrader KT-621 in Atopic Dermatitis
Kymera Therapeutics has started dosing in the Phase 2b BROADEN2 trial for KT-621, an oral STAT6 degrader, in moderate to severe atopic dermatitis. Results are expected by mid-2027. The Phase 1b trial results are anticipated in December 2025. A Phase 2b trial for asthma will begin in early 2026. No results have been reported yet.
Kymera Therapeutics Inc. has announced the initiation of dosing in the BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. Data from the BROADEN2 trial are expected to be reported by mid-2027. The company also completed dosing in the KT-621 BroADen Phase 1b trial for atopic dermatitis, with results anticipated in December 2025. Additionally, Kymera plans to initiate the BREADTH Phase 2b trial of KT-621 in moderate to severe asthma in the first quarter of 2026. No results from these studies have been presented yet; all are scheduled for future reporting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591724-en) on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
